These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. HIP ATTACK Investigators Lancet; 2020 Feb; 395(10225):698-708. PubMed ID: 32050090 [TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S; Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879 [TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial. Loeb M; Roy A; Dokainish H; Dans A; Palileo-Villanueva LM; Karaye K; Zhu J; Liang Y; Goma F; Damasceno A; Alhabib KF; Yonga G; Mondo C; Almahmeed W; Al Mulla A; Thanabalan V; Rao-Melacini P; Grinvalds A; McCready T; Bangdiwala SI; Yusuf S; Lancet Glob Health; 2022 Dec; 10(12):e1835-e1844. PubMed ID: 36400089 [TBL] [Abstract][Full Text] [Related]
12. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G; Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069 [TBL] [Abstract][Full Text] [Related]
13. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P; Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988 [TBL] [Abstract][Full Text] [Related]
14. The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery. Lamy A; Tong W; Mian R; Vincent J; Szczeklik W; Biccard BM; Duceppe E; Franzosi MG; Srinathan SK; Meyhoff CS; Parlow J; Xavier D; Devereaux PJ Am J Cardiovasc Drugs; 2022 Jan; 22(1):83-91. PubMed ID: 34308517 [TBL] [Abstract][Full Text] [Related]
15. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG; Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924 [TBL] [Abstract][Full Text] [Related]
16. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C; Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545 [TBL] [Abstract][Full Text] [Related]
17. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. HALT-IT Trial Collaborators Lancet; 2020 Jun; 395(10241):1927-1936. PubMed ID: 32563378 [TBL] [Abstract][Full Text] [Related]
18. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Schreuder FHBM; van Nieuwenhuizen KM; Hofmeijer J; Vermeer SE; Kerkhoff H; Zock E; Luijckx GJ; Messchendorp GP; van Tuijl J; Bienfait HP; Booij SJ; van den Wijngaard IR; Remmers MJM; Schreuder AHCML; Dippel DW; Staals J; Brouwers PJAM; Wermer MJH; Coutinho JM; Kwa VIH; van Gelder IC; Schutgens REG; Zweedijk B; Algra A; van Dalen JW; Jaap Kappelle L; Rinkel GJE; van der Worp HB; Klijn CJM; Lancet Neurol; 2021 Nov; 20(11):907-916. PubMed ID: 34687635 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Righini M; Galanaud JP; Guenneguez H; Brisot D; Diard A; Faisse P; Barrellier MT; Hamel-Desnos C; Jurus C; Pichot O; Martin M; Mazzolai L; Choquenet C; Accassat S; Robert-Ebadi H; Carrier M; Le Gal G; Mermilllod B; Laroche JP; Bounameaux H; Perrier A; Kahn SR; Quere I Lancet Haematol; 2016 Dec; 3(12):e556-e562. PubMed ID: 27836513 [TBL] [Abstract][Full Text] [Related]
20. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR; Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]